# PT-141 (Bremelanotide): The Approved-Drug Record, Read Straight > PT-141 is the research designation for bremelanotide, a melanocortin agonist FDA-approved in 2019 for low sexual desire in premenopausal women. The trials, the dispute, the tolerability record — cited. It works on the brain, not on blood flow. The benefit in its approved population is real and statistically significant — and openly disputed as small. Here is the record, cited line by line. ## The short version PT-141 is another name for **bremelanotide**, a lab-made peptide (a short chain of amino acids) that the U.S. Food and Drug Administration approved in June 2019 [6]. It is approved for one thing only: low sexual desire that causes real personal distress in women who have not yet reached menopause. Doctors call that condition HSDD (hypoactive sexual desire disorder — persistent low sexual desire that bothers the person who has it). Every other use you may read about — in men, for erectile difficulty, in older women — is *off-label*, meaning it was never part of the approval and the evidence behind it is early. PT-141 acts on the brain's desire circuitry, not on blood vessels, which makes it a different kind of drug from the more familiar erection pills. The benefit in trials was statistically real but small, and the most common problem was nausea. ## What the record on PT-141 actually says Bremelanotide — the drug sold under the development code PT-141 — earned its first regulatory approval in the United States in June 2019, for acquired, generalized HSDD in premenopausal women, given as a 1.75 mg injection under the skin, as needed [6]. That is the whole approved indication. It is not approved for men, for postmenopausal women, for erectile dysfunction, or for sexual "performance," and this site does not present any of those uses as established. The approval rested on two identical Phase 3 randomized controlled trials, known together as RECONNECT, in 1,267 premenopausal women with HSDD [3]. Both trials met their two main goals against placebo: a statistically significant improvement in sexual desire and a statistically significant reduction in the distress that low desire was causing [3]. A 52-week open-label extension then followed 684 of those women and found no new safety surprises, with the effect on desire sustained over a year of use [4]. That is the established core. What follows it on this site is the part the headlines usually skip: the size of the benefit is modest and openly contested, and the tolerability cost — led by nausea — is real. We separate the two cleanly. The cited trial and label evidence sits in one set of pages; a clearly-marked, unverified layer of community field reports sits apart and is never mixed into the citations. ## PT-141 peptide: a melanocortin (MC3R/MC4R) agonist The **PT-141 peptide** is a synthetic cyclic heptapeptide — a ring of seven amino acids — built as an analogue of alpha-MSH, a natural signalling molecule the body makes from a precursor protein called POMC [1]. Its ring structure makes it sturdier than the straight-chain melanocortin peptides it is related to. Mechanistically, PT-141 is a *melanocortin receptor agonist*: a drug that switches on melanocortin receptors — a family of five brain-and-skin receptors (MC1R through MC5R) that respond to alpha-MSH. PT-141 targets the central nervous-system members of that family, chiefly the **melanocortin 4 receptor (MC4R)** and secondarily MC3R [1]. Activating MC4R in hypothalamic circuits is thought to engage the brain's dopamine pathways tied to sexual motivation [1]. Crucially, that is a *central* action. PT-141 does not relax the smooth muscle of blood vessels the way the erection-focused drugs do, which is why it represents a genuinely different pharmacological route to the same broad area of sexual function. [How PT-141 works](/research) is covered in full on the research page. ## Where PT-141 sits, and what it is not PT-141 is a real, approved prescription medicine — not an unapproved research curiosity. But "approved" is precise here, not general: the approval is one indication wide. The same molecule sold online as a "PT-141 research chemical" is a separate, laboratory-only material, outside the pharmaceutical approval framework, with no regulatory oversight of its identity, purity, or concentration [11] — it is not the finished approved drug product. It is also worth correcting two common errors up front. PT-141 does not raise testosterone, and it does not work through the hormonal axis that governs testosterone [12]. And it is not an erection pill that acts on blood vessels; its action is in the brain [1]. The pages here are organized around the published record: the [PT-141 clinical trials](/clinical-trials) and what they measured, the honest [PT-141 side effects](/side-effects) profile, the [PT-141 dosage in the literature](/dosage), and the [references and citations](/references) behind every figure. --- A broadsheet reading of the PT-141 (bremelanotide) record — the one approved indication set in banner type, the modest measured effect printed beside the re-analysis that contests it, the nausea-led tolerability cost run in full, and the unverified field reports kept on their own torn dispatch; no clinic behind the masthead and nothing here dosed, dispensed, or sold.